Literature DB >> 8357549

Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.

M C Lazanas, G A Tsekes, S Papandreou, N Harhalakis, A Scandali, E Nikiforakis, G Saroglou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8357549     DOI： 10.1097/00002030-199307000-00020

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

Authors:  J P Gangneux; A Sulahian; Y J Garin; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 3.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

4.  Liposomal amphotericin B and leishmaniasis: dose and response.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  J Glob Infect Dis       Date:  2010-05

5.  Leishmaniases in Northern Greece: seroprevalence of the infection and incidence of the disease during the period 2001-2006.

Authors:  E Diza; A Kansouzidou; S Gerou; E Vezyri; S Metallidis; A Antoniadis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-30       Impact factor: 3.267
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.